Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial

被引：0
|
作者：
Qifu Li
Qiqi Zhang
Rui Wang
Tianpei Hong
机构：
[1] The First Affiliated Hospital of Chongqing Medical University,Department of Endocrinology
[2] Lilly Suzhou Pharmaceutical Co.,Department of Endocrinology and Metabolism
[3] Ltd,undefined
[4] Shanghai Branch,undefined
[5] Peking University Third Hospital,undefined
来源：
Diabetes Therapy | 2022年 / 13卷
关键词：
Dulaglutide; GLP-1 receptor agonist; Basal insulin; Type 2 diabetes; Glycemic pattern;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：161 / 173
页数：12
相关论文
共 50 条
  • [1] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Li, Qifu
    Zhang, Qiqi
    Wang, Rui
    Hong, Tianpei
    [J]. DIABETES THERAPY, 2022, 13 (01) : 161 - 173
  • [2] Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
    Kuang, Jian
    Zhu, Jiankun
    Liu, Siying
    Li, Quanmin
    [J]. DIABETES THERAPY, 2020, 11 (10) : 2329 - 2339
  • [3] Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
    Jian Kuang
    Jiankun Zhu
    Siying Liu
    Quanmin Li
    [J]. Diabetes Therapy, 2020, 11 : 2329 - 2339
  • [4] Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
    Yan Li
    Ling Li
    Yong De Peng
    Guang Yao Song
    Shan Dong Ye
    Li Ying Du
    Jia Ning Hou
    Qiu He Ji
    [J]. Diabetes Therapy, 2019, 10 : 1435 - 1452
  • [5] Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
    Li, Yan
    Li, Ling
    Peng, Yong De
    Song, Guang Yao
    Ye, Shan Dong
    Du, Li Ying
    Hou, Jia Ning
    Ji, Qiu He
    [J]. DIABETES THERAPY, 2019, 10 (04) : 1435 - 1452
  • [6] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Patel, Hiren
    Munir, Kashif
    Sutherland, Sindee
    Karanikas, Chrisanthi A.
    Konig, Manige
    [J]. DIABETES THERAPY, 2019, 10 (06) : 2321 - 2330
  • [7] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Hiren Patel
    Kashif Munir
    Sindee Sutherland
    Chrisanthi A. Karanikas
    Manige Konig
    [J]. Diabetes Therapy, 2019, 10 : 2321 - 2330
  • [8] Dulaglutide decreases liver enzymes in people with type 2 diabetes: a post-hoc analysis of the AWARD programme
    Haupt, A.
    Cusi, K.
    Sattar, N.
    Garcia-Perez, L. -E.
    Pavo, I.
    Yu, M.
    Robertson, K. E.
    [J]. DIABETOLOGIA, 2017, 60 : S574 - S575
  • [9] Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naive Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1
    Li, Yi Ming
    Zhang, Li Hui
    Li, Xue Jun
    Zhang, Bin
    Hou, Jia Ning
    Tong, Nan Wei
    [J]. DIABETES THERAPY, 2020, 11 (05) : 1077 - 1090
  • [10] Dulaglutide Treatment Reduces Glycemic Excursions in People with Type 2 Diabetes: A Post-hoc Analysis of Six Phase 3 Randomized Clinical Trials
    Charpentier, Guillaume
    Garcia-Perez, Luis E.
    Thieu, Vivian T.
    Jia, Nan
    Jacobson, Jennie G.
    Pechtner, Valeria
    [J]. DIABETES, 2017, 66 : A623 - A623
12345